
Pacira Pharmaceuticals (PCRX) Stock Forecast & Price Target
Pacira Pharmaceuticals (PCRX) Analyst Ratings
Bulls say
Pacira BioSciences, Inc. is projected to achieve substantial revenue growth, with forecasts for 2025 increased by 4-10%, leading to anticipated total revenue of $775 million, a 10.6% year-over-year increase. The company's gross margins are expected to improve to the 76%-78% range, indicating enhanced operational efficiency. Additionally, significant investments in research and development, projected to rise by 21%-42% year-over-year, underscore the commitment to advancing its product pipeline, particularly focusing on PCRX-201, which may further bolster future revenue growth.
Bears say
Pacira BioSciences faces a challenging outlook due to anticipated revenue growth rates that are perceived as low, with guidance suggesting 3-9% year-over-year growth, which may not meet market expectations. The company's projected adjusted selling, general, and administrative expenses are high, estimated between $290-320 million, potentially exceeding operational efficiencies and straining profitability. Furthermore, concerns surrounding Exparel's market exclusivity, coupled with a conservative revenue forecast and a discount rate of 10% in the discounted cash flow analysis, contribute to a bearish sentiment on the stock's long-term performance.
This aggregate rating is based on analysts' research of Pacira Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Pacira Pharmaceuticals (PCRX) Analyst Forecast & Price Prediction
Start investing in Pacira Pharmaceuticals (PCRX)
Order type
Buy in
Order amount
Est. shares
0 shares